Oncology Small Molecule Drugs Market Forecast, Trend Analysis & Competition Tracking: Global Market Insights 2019 to 2029

Published on : Jun-2019 | List of Tables : 53 | List of Figures : 215 | No. of Pages : 170 | Report Code : FACT3747MR |

Oncology Small Molecule Drugs Market in Numbers 

  • Global sales of oncology small molecule drugs were valued at ~US$ 63 Bn in 2018, in line with the widespread prevalence of cancer and subsequent need for oral, easily absorbable, and effective medicines.
  • The market for oncology small molecule drugs is envisaged to register ~6% CAGR through 2029, primarily driven by rapid technological advancement in healthcare sector that continues to pave way for new and improved product development.
  • North America, spearheaded by the U.S., is anticipated to remain the leading as well as high growth market for oncology small molecule drugs during the foreseeable period. With high treatment seeking rate and favorable reimbursement scenarios for cancer treatment, the US is estimated to witness revenues worth ~US$ 30 Bn in 2019.
  • Addition of new products to portfolios through partnerships, and increasing the number of molecules in early phase of drug development will remain among the key trends shaping the competition landscape of oncology small molecule drugs market. 
oncology small molecule drugs market snapshot

Competition Landscape 

According to the Fact.MR study, the oncology small molecule drugs market will continue to remain consolidated with top five players, including Novartis Ag, Astrazeneca, Genentech, Pfizer, and Abbvie, accounting for ~47% market value share.  These players are emphasizing strong regional presence, robust R&D, new launches, and diverse offerings to stay ahead of the competition in oncology small molecule drugs market, which compels companies to enter strategic collaborations with recognized biopharma companies. For instance, recently in June 2019, Pfizer announced the decision to buy the oncology specialist Array BioPharma, marking an important acquisition beefing up the former’s oncology offerings with two marketed drugs - BRAF inhibitor Braftovi, and MEK inhibitor Mektovi. These two drugs have been approved as a part of the combination treatment for melanoma, and have delivered proven positive results in case of colon cancer. 

Mid-level players, such as Roche, Bayer, Genzyme Corporation (Sanofi), and Eli Lilly and Company, are focusing on penetration into developing economies, looking at their market attractiveness. Development of novel treatment options to appeal a wider patient pool will be a priority strategy adopted by prominent players in this category. The market entrants, on the other hand, are likely to remain focused on expansion of the manufacturing capacities to better their foothold in local and regional markets. Amid the growing competition in the oncology small molecule drugs market, partakers are vying to squeeze profit margins by developing low-cost variants, with an objective to firm up in developing regions.    

oncology small molecule drugs market competition analysis

For more valuable insights into the oncology small molecule drugs market, request for the report sample 

Key Factors Shaping Growth of the Oncology Small Molecule Drugs Market 

  • High prevalence of cancer, coupled with the notable preference for more effective drugs that can easily enter and get absorbed in the cells is primarily boosting sales of oncology small molecule drugs.
  • Increasing awareness about the availability of novel and easily absorbable drugs for cancer treatment is providing an impetus to oncology small molecule drugs sales.
  • Modulating the immune system via a small-molecule approach offers several unique benefits that are complementary to, and potentially synergistic with, biologic modalities. An increasing number of biopharma companies are thus utilizing ‘selective targeting small molecules’ that accurately exploit the vulnerabilities in cancer cells. Such a pragmatic approach towards cancer is likely to create a plethora of opportunities in terms of new product developments in the oncology small molecule drugs market.
  • While small molecules account for ~70% of the newly developed molecular entities (NME), as approved by the FDA in 2018, it is highly likely that industry giants will refocus their oncology drug development strategies around the use of these small molecules. Subsequent approvals of oncology small molecule drugs are also creating a steady stream of opportunities in the market. For instance, Pfizer’s Daurismo (glasdegib) received an approval for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients.
  • Availability of multiple immunomodulatory (IMD) agents, with comparable mechanism of action and different routes of administration or structures, can potentially provide useful alternative modalities for personalized cancer treatment. Such advances are likely to spur the demand for oncology small molecule drugs in the forthcoming years.
  • Pharma researchers are increasingly pushing the envelope to find novel therapies, and leveraging next-generation technology to introduce advanced oncology small molecule drugs in market, promising reliability of the treatment.
oncology small molecule drugs market 01

For more intelligence into the oncology small molecule drugs market, request for the report sample 

Key Challenges in the Oncology Small Molecule Drugs Market 

  • Stringent regulatory framework related to approvals of critical drugs, including oncology small molecule drugs, has been a longstanding factor delaying the entire approval process, and thus the subsequent launch of life-saving medicines. This has been particularly the scenario in Japan. The presence of stringent regulatory pathways for new molecules in various regions has become a key challenge limiting the growth of partakers in the oncology small molecule drugs market.
  • Continued dearth of cancer treatment drugs, with just 55 novel drugs receiving regulatory approval during 2012 – 2016, is also impeding the growth of oncology small molecule drugs market. Region-specific availability of over half of the approved cancer drugs due to high price point, lower healthcare spending capabilities of patients, and stringent regulations, continues to limit growth in the oncology small molecule drugs market.
  • Limited reimbursement coverage in many countries has been resulting into expensive cancer treatment, making it highly inaccessible to a sizeable patient population. Though the reimbursement scenario is being altered in several regions, it is not rapid enough to provide access to several expensive drugs.

Oncology Small Molecule Drugs Market – Additional Insight

Targeted Therapy Drugs – Most Promising Drug Class in Oncology Small Molecule Drugs Market

Growing traction for targeted therapy as a vital type of cancer treatment continues to expand the bandwidth of opportunities for the manufacturers of oncology small molecule drugs. Development, quicker regulatory approval, and subsequent adoption of small molecule drugs to block the process that aids cancer cells multiply and spread, continue to uplift the oncology small molecule drugs market. Furthermore, growing FDA approvals of oncology small molecule drugs, such as larotrectinib (Vitrakvi) as a type of targeted therapy that aims a specific genetic change known as NTRK fusion, continue to add gains into the market.

Oncology Small Molecule Drugs Market – Research Methodology

oncology small molecule drugs market taxonomy

An accurate methodology and holistic approach forms the foundation of the valuable information presented in the oncology small molecule drugs market. The Fact.MR study offers thorough information about the growth forecast of oncology small molecule drugs sector, along with a systematic breakdown of the determinants impacting the growth of the market.

In-depth primary as well as secondary research has been performed to accumulate and present incisive insights into the forecast analysis of oncology small molecule drugs market. The report on oncology small molecule drugs market has also undergone numerous validation tunnels to ensure that that information mentioned in the report is unique and one of its kind.

Request Methodology of this Report.

A recently compiled report of Fact.MR, titled “Oncology Small Molecule Drugs Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2019-2029,” provides a detailed analysis on the global oncology small molecule drugs market. Size of the oncology small molecule drugs market has been analyzed in a comprehensive way and is presented in terms of value (US$ Mn). The report provides a detailed analysis and forecast on the key segments of the market and oncology small molecule drugs market competitive landscape. 

Chapter 1 - Oncology Small Molecule Drugs Market Executive Summary 

A succinct summery of the oncology small molecule drugs market is provided in the first chapter of the report, which offers a synopsis of key findings in the market, and details about the market structure. Opportunity assessment for various companies that are operating in the oncology small molecule drugs market is presented in an exhaustive way with the aid of Wheel of Fortune. Significant trends that are shaping the growth of the oncology small molecule drugs market have also been presented in this part of the report. 

Chapter 2- Oncology Small Molecule Drugs Market Overview 

The report provides a concise overview of the oncology small molecule drugs market, which encompassed the market introduction and definition of the key product – oncology small molecule drugs. An organized breakdown of the oncology small molecule drugs market is provided in this chapter, entailing the scope of the research involved. 

Chapter 3- Oncology Small Molecule Drugs Market Key Trends 

In this section of the report, various key trends that can shape the growth of the market during the foreseeable period have been jolted down in a comprehensive way. Several trends related to the product innovation and key market developments have also been presented in the report. 

Chapter 4 - Key Success Factors 

This chapter of the report sheds light on key regulations impacting the growth of the oncology small molecule drugs market. Epidemiology of the different types of cancer has been presented, region wise, along with a pipeline assessment of oncology small molecule drugs, 

Chapter 5- Global Oncology Small Molecule Drugs Market (in Value or Size in US$ Mn) Analysis 2014-2018 and Forecast, 2019-2029 

The comprehensive analysis and forecast on oncology small molecule drugs market has been presented in this section of the report. Significant numbers, including the historical, current and forecast size of the oncology small molecule drugs market have been given in this chapter. 

Chapter 6- Oncology Small Molecule Drugs Market Background 

This chapter of the report sheds light on the market background, along with the factors that are driving the demand for oncology small molecule drugs. This chapter also gives information about the demand for the raw materials and forecast equation to help the readers gauge the growth of oncology small molecule drugs market. 

Chapter 7 - Global Oncology Small Molecule Drugs Market Analysis 2014-2018 and Forecast 2019-2029, By Drug Class 

This chapter of the report on oncology small molecule drugs market offers information about the significant market particulars, breakdown and forecast of the industry on the basis of drug class. Based on drug class, the oncology small molecule drugs market is segmented into Chemotherapy drugs, immunomodulating drugs, and targeted therapy drugs. 

Chapter 8 - Global Oncology Small Molecule Drugs Market Analysis 2014-2018 and Forecast 2019-2029, By Indication

This chapter of the report on oncology small molecule drugs market provides details about the market particulars, breakdown and forecast of the industry based on indication. On the basis of indication, the oncology small molecule drugs market is segmented into non-small cell lung cancer (NSCLC), Lymphoma, prostate cancer, leukemia, multiple myeloma, renal cell carcinoma, breast cancer, and melanoma, 

Chapter 9 - Global Oncology Small Molecule Drugs Market Analysis 2014-2018 and Forecast 2019-2029, By Route of Administration 

This section of the report on oncology small molecule drugs market offers details related to the market particulars, breakdown and forecast of the industry based on indication. Based on route of administration, the oncology small molecule drugs market is bifurcated into injectable and oral. 

Chapter 10 - Global Oncology Small Molecule Drugs Market Analysis 2014-2018 and Forecast 2019-2029, By Distribution Channel 

This part of the report on oncology small molecule drugs market gives detailed information about the market particulars, breakdown and forecast of the industry based on distribution channel. Based on distribution channel, oncology small molecule drugs market is segmented into hospital pharmacies, retail pharmacies, specialty clinics, and online pharmacies. 

Chapter 11 - Global Oncology Small Molecule Drugs Market Analysis 2014-2018 and Forecast 2019-2029, By Region 

This section of the report on oncology small molecule drugs market presents information about the market particulars, breakdown and forecast of the industry based on various regions. 

Chapter 12- North America Oncology Small Molecule Drugs Market Analysis 2014-2018 and Forecast 2019-2029 

This chapter of the report on oncology small molecule drugs market offers incisive insights related to North America oncology small molecule drugs market, and also provides information pertaining to the regional trends that are shaping the growth of market in this region. 

Chapter 13- Latin America Oncology Small Molecule Drugs Market Analysis 2014-2018 and Forecast 2019-2029 

This chapter of the report on oncology small molecule drugs market offers incisive insights related to Latin America oncology small molecule drugs market, and also offers information about the regional trends that are shaping the growth of market in this region. 

Chapter 14- Europe Oncology Small Molecule Drugs Market Analysis 2014-2018 and Forecast 2019-2029 

This section of the report on oncology small molecule drugs market provides valuable insights related to Europe oncology small molecule drugs market, and also offers information about the regional trends that are shaping the growth of market in this region. 

Chapter 15- South Asia Oncology Small Molecule Drugs Market Analysis 2014-2018 and Forecast 2019-2029 

This chapter of the oncology small molecule drugs market offers actionable insights related to Europe oncology small molecule drugs market. 

Chapter 16- East Asia Oncology Small Molecule Drugs Market Analysis 2014-2018 and Forecast 2019-2029 

This chapter of the oncology small molecule drugs market gives authentic information about the valuable insights related to the position of oncology small molecule drugs market in different countries across East Asia. 

Chapter 17- Oceania Oncology Small Molecule Drugs Market Analysis 2014-2018 and Forecast 2019-2029 

This section of the report offers authentic information about the actionable insights pertaining to the position of oncology small molecule drugs market in different countries across Oceania, such as Australia and New Zealand. 

Chapter 18- Middle East & Africa Oncology Small Molecule Drugs Market Analysis 2014-2018 and Forecast 2019-2029 

This part of the report provides accurate information about the valuable insights related to oncology small molecule drugs market in different parts of Middle East & Africa. 

Chapter 19 – Oncology Small Molecule Drugs Market Structure Analysis 

This chapter of the report on the market structure analysis of oncology small molecule drugs market offers comprehensive outlook of the competition dashboard along with market structure, company share analysis, and a list of leading and spearheading players in the market. 

Chapter 20 - Competition Analysis 

This weighted chapter of the Fact.MR report provides detailed assessment of the oncology small molecule drugs market’s structure, and carries company profiles of all leading market players. The report carries company profiles of

  • Novartis AG
  • Sanofi S.A.
  • AbbVie Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • AstraZeneca plc.

1. Executive Summary
    1.1. Global Market Outlook
    1.2. Market Trends
    1.3. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Key Market Trends
    3.1. Key Trends Impacting the Market
    3.2. Product Innovation / Development Trends
4. Key Success Factors
    4.1. Key Regulations
    4.2. Epidemiology of Various Cancer Types, By Region
    4.3. Pipeline Assessment
5. Global Oncology Small Molecule Drug Market (in Value or Size in US$ Mn) Analysis 2014-2018 and Forecast, 2019-2029
    5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018
    5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2029
        5.2.1. Y-o-Y Growth Trend Analysis
        5.2.2. Absolute $ Opportunity Analysis
6. Market Background
    6.1. Macro-Economic Factors
        6.1.1. Global GDP Growth Outlook
        6.1.2. Increasing R & D Expenditure
    6.2. Forecast Factors - Relevance & Impact
        6.2.1. Increasing Prevalence of Cancer
        6.2.2. Increasing Early Diagnosis Rate of Cancer
        6.2.3. Increasing Treatment Seeking Rate 
        6.2.4. Increasing Availability of Treatment Options for Cancer
        6.2.5. Adoption of Small Molecule in Oncology
    6.3. Market Dynamics
        6.3.1. Drivers
        6.3.2. Restraints
        6.3.3. Opportunity Analysis
7. Global Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029, By Drug Class 
    7.1. Introduction / Key Findings
    7.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2014 - 2018
    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2019 - 2029
        7.3.1. Chemotherapy Drugs
            7.3.1.1. Alkylating Agents 
            7.3.1.2. Antimetabolites
            7.3.1.3. Other Drugs 
        7.3.2. Immunomodulating Drugs
        7.3.3. Targeted Therapy Drugs
            7.3.3.1. Proteasome Inhibitors 
            7.3.3.2. Tyrosine Kinase Inhibitors
            7.3.3.3. mTOR Inhibitors 
            7.3.3.4. Others
        7.3.4. Hormonal Therapy
    7.4. Market Attractiveness Analysis By Drug Class 
8. Global Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029, By Indication 
    8.1. Introduction / Key Findings
    8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2014 - 2018
    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2019 - 2029
        8.3.1. Non-small Cell Lung Cancer (NSCLC)
        8.3.2. Renal Cell Carcinoma
        8.3.3. Breast Cancer
        8.3.4. Prostate Cancer
        8.3.5. Multiple Myeloma
        8.3.6. Melanoma
        8.3.7. Lymphoma
        8.3.8. Leukemia
        8.3.9. Others
    8.4. Market Attractiveness Analysis By Indication
9. Global Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029, By Route of Administration 
    9.1. Introduction / Key Findings
    9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2014 - 2018
    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2019 - 2029
        9.3.1. Oral
        9.3.2. Injectable
    9.4. Market Attractiveness Analysis By Route of Administration
10. Global Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029, by Distribution Channel
    10.1. Introduction / Key Findings
    10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2014 - 2018
    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2019 - 2029
        10.3.1. Hospital Pharmacies
        10.3.2. Retail Pharmacies
        10.3.3. Specialty Clinics
        10.3.4. Online Pharmacies
    10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029, by Region
    11.1. Introduction
    11.2. Historical Market Size (US$ Mn) Analysis By Region, 2014 - 2018
    11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2019 - 2029
        11.3.1. North America
        11.3.2. Latin America
        11.3.3. Europe
        11.3.4. East Asia
        11.3.5. South Asia
        11.3.6. Oceania
        11.3.7. Middle East and Africa (MEA)
    11.4. Market Attractiveness Analysis By Region
12. North America Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029
    12.1. Introduction
    12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        12.3.1.  By Country
            12.3.1.1. U.S.
            12.3.1.2. Canada
        12.3.2. By Drug Class
        12.3.3. By Indication
        12.3.4. By Route of Administration
        12.3.5. By Distribution Channel
    12.4. Market Attractiveness Analysis
        12.4.1. By Country
        12.4.2. By Drug Class
        12.4.3. By Indication
        12.4.4. By Route of Administration
        12.4.5. By Distribution Channel
    12.5. Key Market Participants - Intensity Mapping
    12.6. Drivers and Restraints - Impact Analysis
13. Latin America Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029
    13.1. Introduction
    13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        13.3.1.  By Country
            13.3.1.1. Brazil
            13.3.1.2. Mexico
            13.3.1.3. Rest of Latin America
        13.3.2. By Drug Class
        13.3.3. By Indication
        13.3.4. By Route of Administration
        13.3.5. By Distribution Channel
    13.4. Market Attractiveness Analysis
        13.4.1. By Country
        13.4.2. By Drug Class
        13.4.3. By Indication
        13.4.4. By Route of Administration
        13.4.5. By Distribution Channel
    13.5. Key Market Participants - Intensity Mapping
    13.6. Drivers and Restraints - Impact Analysis
14. Europe Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029
    14.1. Introduction
    14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        14.3.1.  By Country
            14.3.1.1. Germany
            14.3.1.2. Italy
            14.3.1.3. France
            14.3.1.4. U.K.
            14.3.1.5. Spain
            14.3.1.6. BENELUX
            14.3.1.7. Russia
            14.3.1.8. Rest of Europe
        14.3.2. By Drug Class
        14.3.3. By Indication
        14.3.4. By Route of Administration
        14.3.5. By Distribution Channel
    14.4. Market Attractiveness Analysis
        14.4.1. By Country
        14.4.2. By Drug Class
        14.4.3. By Indication
        14.4.4. By Route of Administration
        14.4.5. By Distribution Channel
    14.5. Key Market Participants - Intensity Mapping
    14.6. Drivers and Restraints - Impact Analysis
15. South Asia Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029
    15.1. Introduction
    15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        15.3.1.  By Country
            15.3.1.1. India
            15.3.1.2. Thailand
            15.3.1.3. Indonesia
            15.3.1.4. Malaysia
            15.3.1.5. Rest of South Asia
        15.3.2. By Drug Class
        15.3.3. By Indication
        15.3.4. By Route of Administration
        15.3.5. By Distribution Channel
    15.4. Market Attractiveness Analysis
        15.4.1. By Country
        15.4.2. By Drug Class
        15.4.3. By Indication
        15.4.4. By Route of Administration
        15.4.5. By Distribution Channel
    15.5. Key Market Participants - Intensity Mapping
    15.6. Drivers and Restraints - Impact Analysis
16. East Asia Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029
    16.1. Introduction
    16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        16.3.1.  By Country
            16.3.1.1. China
            16.3.1.2. Japan
            16.3.1.3. South Korea
        16.3.2. By Drug Class
        16.3.3. By Indication
        16.3.4. By Route of Administration
        16.3.5. By Distribution Channel
    16.4. Market Attractiveness Analysis
        16.4.1. By Country
        16.4.2. By Drug Class
        16.4.3. By Indication
        16.4.4. By Route of Administration
        16.4.5. By Distribution Channel
    16.5. Key Market Participants - Intensity Mapping
    16.6. Drivers and Restraints - Impact Analysis
17. Oceania Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029
    17.1. Introduction
    17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        17.3.1.  By Country
            17.3.1.1. Australia
            17.3.1.2. New Zealand
        17.3.2. By Drug Class
        17.3.3. By Indication
        17.3.4. By Route of Administration
        17.3.5. By Distribution Channel
    17.4. Market Attractiveness Analysis
        17.4.1. By Country
        17.4.2. By Drug Class
        17.4.3. By Indication
        17.4.4. By Route of Administration
        17.4.5. By Distribution Channel
    17.5. Key Market Participants - Intensity Mapping
    17.6. Drivers and Restraints - Impact Analysis
18. Middle East and Africa Oncology Small Molecule Drug Market Analysis 2014-2018 and Forecast 2019-2029
    18.1. Introduction
    18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2018
    18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
        18.3.1.  By Country
            18.3.1.1. GCC Countries
            18.3.1.2. Turkey
            18.3.1.3. Northern Africa
            18.3.1.4. South Africa
            18.3.1.5. Rest of Middle East and Africa
        18.3.2. By Drug Class
        18.3.3. By Indication
        18.3.4. By Route of Administration
        18.3.5. By Distribution Channel
    18.4. Market Attractiveness Analysis
        18.4.1. By Country
        18.4.2. By Drug Class
        18.4.3. By Indication
        18.4.4. By Route of Administration
        18.4.5. By Distribution Channel
    18.5. Key Market Participants - Intensity Mapping
    18.6. Drivers and Restraints - Impact Analysis
19. Market Structure Analysis
    19.1. Market Analysis by Tier of Companies 
    19.2. Market Share Analysis of Top Players
    19.3. Market Presence Analysis
        19.3.1. By Regional footprint of Players
        19.3.2. Product & Channel foot print by Players
20. Competition Analysis
    20.1. Competition Dashboard
    20.2. Competition Benchmarking
    20.3. Competition Deep Dive 
        20.3.1. Novartis AG
            20.3.1.1. Overview
            20.3.1.2. Product Portfolio
            20.3.1.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.1.4. Sales Footprint
            20.3.1.5. Strategy Overview
                20.3.1.5.1. Marketing Strategy
                20.3.1.5.2. Product Strategy
                20.3.1.5.3. Channel Strategy
        20.3.2. Pfizer Inc.
            20.3.2.1. Overview
            20.3.2.2. Product Portfolio
            20.3.2.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.2.4. Sales Footprint
            20.3.2.5. Strategy Overview
                20.3.2.5.1. Marketing Strategy
                20.3.2.5.2. Product Strategy
                20.3.2.5.3. Channel Strategy
        20.3.3. Amgen Inc.
            20.3.3.1. Overview
            20.3.3.2. Product Portfolio
            20.3.3.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.3.4. Sales Footprint
            20.3.3.5. Strategy Overview
                20.3.3.5.1. Marketing Strategy
                20.3.3.5.2. Product Strategy
                20.3.3.5.3. Channel Strategy
        20.3.4. F. Hoffman - La Roche Ltd. (Genentech, Inc.)
            20.3.4.1. Overview
            20.3.4.2. Product Portfolio
            20.3.4.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.4.4. Sales Footprint
            20.3.4.5. Strategy Overview
                20.3.4.5.1. Marketing Strategy
                20.3.4.5.2. Product Strategy
                20.3.4.5.3. Channel Strategy
        20.3.5. Eli Lilly and Company
            20.3.5.1. Overview
            20.3.5.2. Product Portfolio
            20.3.5.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.5.4. Sales Footprint
            20.3.5.5. Strategy Overview
                20.3.5.5.1. Marketing Strategy
                20.3.5.5.2. Product Strategy
                20.3.5.5.3. Channel Strategy
        20.3.6. Sanofi S.A. (Genzyme Corporation)
            20.3.6.1. Overview
            20.3.6.2. Product Portfolio
            20.3.6.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.6.4. Sales Footprint
            20.3.6.5. Strategy Overview
                20.3.6.5.1. Marketing Strategy
                20.3.6.5.2. Product Strategy
                20.3.6.5.3. Channel Strategy
        20.3.7. Bristol-Myers Squibb Company
            20.3.7.1. Overview
            20.3.7.2. Product Portfolio
            20.3.7.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.7.4. Sales Footprint
            20.3.7.5. Strategy Overview
                20.3.7.5.1. Marketing Strategy
                20.3.7.5.2. Product Strategy
                20.3.7.5.3. Channel Strategy
        20.3.8. AbbVie Inc.
            20.3.8.1. Overview
            20.3.8.2. Product Portfolio
            20.3.8.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.8.4. Sales Footprint
            20.3.8.5. Strategy Overview
                20.3.8.5.1. Marketing Strategy
                20.3.8.5.2. Product Strategy
                20.3.8.5.3. Channel Strategy
        20.3.9. Bayer AG
            20.3.9.1. Overview
            20.3.9.2. Product Portfolio
            20.3.9.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.9.4. Sales Footprint
            20.3.9.5. Strategy Overview
                20.3.9.5.1. Marketing Strategy
                20.3.9.5.2. Product Strategy
                20.3.9.5.3. Channel Strategy
        20.3.10. Incyte Corporation
            20.3.10.1. Overview
            20.3.10.2. Product Portfolio
            20.3.10.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.10.4. Sales Footprint
            20.3.10.5. Strategy Overview
                20.3.10.5.1. Marketing Strategy
                20.3.10.5.2. Product Strategy
                20.3.10.5.3. Channel Strategy
        20.3.11. Celgene Corporation
            20.3.11.1. Overview
            20.3.11.2. Product Portfolio
            20.3.11.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.11.4. Sales Footprint
            20.3.11.5. Strategy Overview
                20.3.11.5.1. Marketing Strategy
                20.3.11.5.2. Product Strategy
                20.3.11.5.3. Channel Strategy
        20.3.12. AstraZeneca plc
            20.3.12.1. Overview
            20.3.12.2. Product Portfolio
            20.3.12.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.12.4. Sales Footprint
            20.3.12.5. Strategy Overview
                20.3.12.5.1. Marketing Strategy
                20.3.12.5.2. Product Strategy
                20.3.12.5.3. Channel Strategy
        20.3.13. Exelixis Inc.
            20.3.13.1. Overview
            20.3.13.2. Product Portfolio
            20.3.13.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.13.4. Sales Footprint
            20.3.13.5. Strategy Overview
                20.3.13.5.1. Marketing Strategy
                20.3.13.5.2. Product Strategy
                20.3.13.5.3. Channel Strategy
        20.3.14. Millennium Pharmaceuticals, Inc. (Takeda Pharmaceutical Company Ltd)
            20.3.14.1. Overview
            20.3.14.2. Product Portfolio
            20.3.14.3. Profitability by Market Segments (Product/Channel/Region)
            20.3.14.4. Sales Footprint
            20.3.14.5. Strategy Overview
                20.3.14.5.1. Marketing Strategy
                20.3.14.5.2. Product Strategy
                20.3.14.5.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Our Clients

Oncology Small Molecule Drugs Market Forecast, Trend Analysis & Competition Tracking: Global Market Insights 2019 to 2029